Diacylglycerol: efficacy and mechanism of action of an anti-obesity agent.
Obesity is at the forefront of global health issues and directly contributes to many chronic illnesses. Several dietary components show promise in the treatment of obesity, one of which is oil rich in diacylglycerols (DAGs). Present objectives are to examine scientific knowledge concerning DAG to assess evidence supporting the effects on substrate oxidation rates, body weight and fat mass, and blood lipids, and to assess safety, as well as elucidate potential mechanisms of action. DAG can be synthesized by an enzymatic process to produce mainly 1,3-isoform DAG. This 1,3-DAG oil is believed to have the ability to increase beta-oxidation, to enhance body weight loss, to suppress body fat accumulation, and to lower serum triacylglycerol levels postprandially. While certain animal and human studies indicate that consumption of 1,3-DAG has positive physiological effects, others report no effect. The mechanisms of action of DAG are suggested to decrease the resynthesis of chylomicrons as well as shunting them directly to the liver through the portal vein, where they are oxidized. This increased fat oxidation may influence control of food intake by increasing satiety. Further study into the precise mechanism is required to understand its effects. Safety studies show no risks in consuming a diet rich in DAG oil. Overall, consumption of oils with higher amounts of DAG, specifically 1,3-DAG, may be useful in the battle against obesity.
Rudkowska
Iwona
I
School of Dietetics and Human Nutrition, Faculty of Agricultural and Environmental Sciences, McGill University, Montreal, Quebec, Canada.
Roynette
Catherine E
CE
Demonty
Isabelle
I
Vanstone
Catherine A
CA
Jew
Stephanie
S
Jones
Peter J H
PJ
D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use* / Q000633:toxicity; D001823:Body Composition / Q000187:drug effects; D004042:Dietary Fats, Unsaturated / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D004075:Diglycerides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D010084:Oxidation-Reduction; D016896:Treatment Outcome
D019440:Anti-Obesity Agents; D004042:Dietary Fats, Unsaturated; D004075:Diglycerides; D008055:Lipids